stockrow
Friday 6 November 2026
Export TEVA’s income statement to Excel — free account
Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
42.47
0.69
+1.65%
Follow TEVA
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
25.17 | 0.00 | 0.00 | 0.00 | 22.76 | 0.00 | 0.00 | 0.00 | 0.00 | 535.43 |
Piotroski F-Score |
8 | 5 | 6 | 4 | 7 | 5 | 5 | 5 | 3 | 3 |
Altman Z-Score |
0.79 | 0.40 | 0.17 | (0.05) | 0.34 | (0.05) | 0.25 | 0.44 | (0.40) | 0.86 |
P/S ratio |
2.07 | 1.51 | 0.75 | 0.71 | 0.60 | 0.63 | 0.63 | 0.86 | 0.68 | 1.63 |
P/FCF ratio |
30.23 | 31.47 | 13.12 | 9.53 | 17.43 | 14.99 | 18.89 | 5.86 | 3.16 | 5.66 |
Altman Z″-Score (non-manufacturers) |
(0.41) | (0.97) | (0.67) | (0.95) | 0.06 | (0.91) | (0.10) | 0.15 | (1.70) | 1.18 |
Beneish M-Score |
(2.35) | (3.00) | (2.77) | (3.10) | (2.52) | (3.20) | (2.62) | (3.02) | (3.81) | (2.32) |
P/Operating CF |
30.86 | 43.35 | 10.08 | 10.87 | 20.90 | 31.92 | 19.87 | 42.90 | 17.74 | 25.12 |
Dividend Safety Score |
52 | — | — | — | — | — | — | — | — | — |
P/B ratio |
4.52 | 4.63 | 1.47 | 1.23 | 0.85 | 0.96 | 0.71 | 1.00 | 1.01 | 1.14 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.84 | 2.38 | 1.80 | 1.94 | 1.92 | 2.06 | 2.11 | 2.35 | 2.09 | 3.22 |
EV/EBITDA |
15.50 | 19.36 | 18.00 | 0.00 | 9.99 | 0.00 | 27.87 | 13.27 | 0.00 | 19.20 |
EV/Operating CF |
29.71 | 31.60 | 20.87 | 18.23 | 38.11 | 28.21 | 47.63 | 17.53 | 21.01 | 13.51 |
EV/FCF |
41.44 | 49.76 | 31.37 | 26.12 | 55.59 | 48.66 | 62.94 | 15.97 | 9.68 | 11.16 |
Quick Ratio |
0.54 | 0.50 | 0.54 | 0.57 | 0.61 | 0.51 | 0.56 | 0.53 | 0.45 | 0.46 |
Current Ratio |
1.04 | 0.98 | 1.02 | 1.05 | 1.14 | 0.99 | 0.98 | 0.96 | 0.86 | 0.93 |
Net Debt/EBITDA |
4.19 | 7.11 | 10.47 | (20.71) | 6.86 | (11.79) | 19.51 | 8.40 | (2.05) | 9.46 |
Debt/Assets |
41.24% | 45.22% | 45.62% | 48.20% | 48.34% | 51.18% | 46.82% | 47.65% | 45.99% | 38.47% |
Debt/Equity |
2.12 | 3.31 | 2.44 | 2.47 | 2.05 | 2.34 | 1.79 | 1.83 | 1.73 | 1.02 |
Asset Turnover |
0.43 | 0.40 | 0.36 | 0.33 | 0.32 | 0.31 | 0.29 | 0.28 | 0.27 | 0.30 |
Operating CF/Net income |
1.17 | (0.76) | (2.45) | (0.65) | 1.91 | (0.30) | (0.75) | (1.02) | (0.13) | 76.84 |
Capex/Depreciation |
(0.47) | (0.43) | (0.40) | (0.37) | (0.19) | (0.33) | (0.11) | 0.13 | 1.23 | 0.72 |
| 21.21% | (24.27%) | (6.69%) | (24.65%) | 3.74% | (30.55%) | (6.48%) | (15.52%) | (71.10%) | 0.23% | |
| 3.52% | (3.96%) | (1.28%) | (5.34%) | 0.85% | (7.38%) | (1.69%) | (3.65%) | (20.19%) | 0.09% | |
ROIC |
6.37% | 3.07% | 1.09% | (5.08%) | 3.34% | (6.41%) | (0.69%) | 2.02% | (21.74%) | 1.93% |
Return on Tangible Assets |
30.85% | (37.79%) | (9.34%) | (38.70%) | 5.54% | (65.02%) | (16.05%) | (37.84%) | (321.87%) | 1.00% |
Average Days of Receivables |
78.44 | 67.49 | 78.50 | 90.39 | 104.11 | 100.37 | 122.68 | 116.31 | 116.23 | 125.37 |
Research and Development Expense of Revenue |
5.87% | 6.03% | 6.01% | 5.61% | 6.09% | 5.98% | 5.98% | 6.64% | 7.94% | 9.64% |
Selling, General and Administrative Expense of Revenue |
23.02% | 22.38% | 22.07% | 23.08% | 22.22% | 22.04% | 22.54% | 23.06% | 21.65% | 23.49% |
Intangible Assets out of Total Assets |
0.49 | 0.50 | 0.52 | 0.54 | 0.58 | 0.58 | 0.63 | 0.64 | 0.65 | 0.71 |
Share Based Compensation of Revenue |
0.91% | 0.74% | 0.76% | 0.83% | 0.75% | 0.77% | 0.70% | 0.85% | 0.59% | 0.57% |
Graham Net Nets |
(0.53) | (0.86) | (1.92) | (2.21) | (2.50) | (2.51) | (2.71) | (1.98) | (2.39) | (1.14) |
Graham Number |
13.89 | 0.00 | 0.00 | 0.00 | 9.34 | 0.00 | 0.00 | 0.00 | 0.00 | 7.19 |
Earnings Yield |
3.97% | (6.58%) | (4.40%) | (22.25%) | 4.39% | (37.72%) | (9.39%) | (15.05%) | (108.40%) | 0.19% |
Free Cash Flow Yield |
3.31% | 3.18% | 7.62% | 10.49% | 5.74% | 6.67% | 5.29% | 17.05% | 31.68% | 17.67% |
Revenue per Share |
15.07 | 14.63 | 14.16 | 13.45 | 14.41 | 15.21 | 15.48 | 17.90 | 22.03 | 22.94 |
Operating CF per Share |
1.44 | 1.10 | 1.22 | 1.43 | 0.72 | 1.11 | 0.69 | 2.40 | 2.19 | 5.47 |
Capex per Share |
(0.41) | (0.40) | (0.41) | (0.43) | (0.23) | (0.47) | (0.17) | 0.23 | 2.56 | 1.15 |
Free Cash Flow per Share |
1.03 | 0.70 | 0.81 | 1.00 | 0.50 | 0.64 | 0.52 | 2.63 | 4.75 | 6.62 |
Cash per Share |
3.11 | 2.92 | 2.88 | 2.52 | 1.96 | 1.99 | 1.81 | 1.75 | 0.95 | 1.03 |
Shareholders Equity per Share |
6.91 | 4.76 | 7.26 | 7.75 | 10.20 | 10.10 | 13.81 | 15.47 | 18.45 | 36.64 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.91 | 4.76 | 7.26 | 7.75 | 10.20 | 10.10 | 13.81 | 15.47 | 18.45 | 36.64 |
Free Cash Flow |
1,182.00 | 792.00 | 910.00 | 1,110.00 | 547.00 | 705.00 | 566.00 | 2,685.00 | 4,828.00 | 6,326.00 |
Working Capital |
490.00 | (244.00) | 238.00 | 582.00 | 1,546.00 | (159.00) | (210.00) | (528.00) | (2,539.00) | (1,260.00) |
Capital Expenditures |
(467.00) | (455.00) | (458.00) | (480.00) | (251.00) | (511.00) | (182.00) | 239.00 | 2,603.00 | 1,101.00 |
Net Current Asset Value |
(18,888.00) | (21,394.00) | (22,868.00) | (23,362.00) | (23,849.00) | (26,574.00) | (28,943.00) | (31,095.00) | (36,488.00) | (40,836.00) |
EV/EBIT |
22.70 | 40.34 | 65.93 | 0.00 | 17.73 | 0.00 | 0.00 | 30.85 | 0.00 | 32.78 |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.01 | (0.01) | (0.12) | (0.05) |
Price to Operating Income |
16.56 | 25.51 | 27.57 | 0.00 | 5.56 | 0.00 | 0.00 | 11.33 | 0.00 | 16.62 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.25 | 0.23 | 0.20 | 0.23 | 0.22 | 0.25 | 0.27 | 0.27 | 0.28 | 0.19 |
Cash ROIC |
4.18% | 2.99% | 2.92% | 3.40% | 1.50% | 1.80% | 1.29% | 5.78% | 9.25% | 8.81% |
Accounts Receivable Turnover |
5.10 | 5.12 | 4.46 | 3.63 | 3.49 | 3.25 | 2.94 | 2.82 | 3.06 | 3.40 |
Accounts Payable Turnover |
3.52 | 3.53 | 3.65 | 4.45 | 4.81 | 5.14 | 5.24 | 5.09 | 5.57 | 4.93 |
Inventory Turnover |
2.69 | 2.41 | 2.09 | 2.08 | 2.02 | 2.02 | 2.04 | 2.07 | 2.38 | 2.25 |
Average Days of Payables |
111.04 | 94.81 | 115.82 | 86.61 | 74.29 | 71.75 | 67.06 | 67.80 | 64.16 | 78.39 |
Days of Inventory on Hand |
139.46 | 129.41 | 178.98 | 175.94 | 168.22 | 179.91 | 172.61 | 173.11 | 152.70 | 180.03 |
Average Receivables |
3,384.00 | 3,233.50 | 3,552.00 | 4,112.50 | 4,555.00 | 5,128.50 | 5,749.00 | 6,475.00 | 7,325.50 | 6,436.50 |
Average Payables |
2,367.00 | 2,402.50 | 2,244.50 | 1,786.50 | 1,721.00 | 1,737.00 | 1,785.50 | 1,961.00 | 2,113.00 | 2,037.50 |
Average Inventory |
3,093.00 | 3,514.00 | 3,927.00 | 3,825.50 | 4,110.50 | 4,412.50 | 4,576.50 | 4,827.50 | 4,939.00 | 4,460.00 |
Average Assets |
40,037.00 | 41,402.50 | 43,745.00 | 45,838.50 | 49,153.00 | 54,055.00 | 59,076.50 | 65,649.00 | 81,836.00 | 73,645.00 |
Average Common Equity |
6,647.00 | 6,752.50 | 8,361.50 | 9,921.00 | 11,153.00 | 13,062.50 | 15,428.50 | 15,454.00 | 23,243.50 | 29,004.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026